Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q4 FY2026 Earnings Presentation
32 slides from Tarsons Products's earnings presentation, May 23, 2026
Slide 1: Cover letter to BSE and NSE
An ISO 9001 & ISO 13485 Certified Company Date: May 23, 2026 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited Corporate Relationship Department, (“NSE”) 2nd Floor, New Trading Ring, “Exchange Plaza”, 5th Floor, P.J. Towers, Dalal Street, Plot No. C/1, G Block, Mumbai – 400 001 B
Slide 2: Tarsons Products Limited Investor Presentation May 2026
TARSONS PRODUCTS LIMITED Investor Presentation May 2026 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q4 & FY26 Financial & Operational Highlights
Q4 & FY26 Financial & Operational Highlights
Slide 5: Q4 & FY26 Consolidated Revenue Break-up
Q4 & FY26 Consolidated Revenue Break-up Standalone Domestic Standalone Export Revenue Nerbe Revenue Total Consolidated Revenue Revenue (in Rs. crs) (in Rs. crs) (in Rs. crs) (in Rs. crs) +7% +3% +14% +8% 230.0 99.8 102.9 214.4 422.5 89.6 392.4 78.3 +12% -13% +22% +7% 66.2 73.9 120.9 26.9 23.3 23.8 1
Slide 6: Q4 & FY26 Standalone Financial Highlights
Q4 & FY26 Standalone Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Adjusted PAT^ (in Rs. crs) Adjusted Cash PAT# (in Rs. crs) +6% +4% -44% +15% 332.9 105.4 110.1 42.7 111.1 314.2 96.7 -12% -67% 23.8 +4% -4% 37.0 15.7 93.0 97.2 32.6 33.2 31.9 5.2 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26
Slide 7: Q4 & FY26 Consolidated Financial Highlights
Q4 & FY26 Consolidated Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Adjusted PAT^ (in Rs. crs) Adjusted Cash PAT# (in Rs. crs) +8% +7% -48% +21% 422.5 117.9 29.8 112.0 392.4 110.7 92.3 +7% -7% -61% 15.5 +9% 37.0 10.2 33.0 112.7 120.9 34.3 30.2 4.0 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY
Slide 8: Bridge between Standalone & Consolidated PAT – FY26
Bridge between Standalone & Consolidated PAT – FY26 (In Rs. Crs) 22.7 -5.4 4.3 14.3 -4.1 -3.2 FY26 Standalone PAT Interest Income and Interest paid to Amortisation on Nerbe PAT FY26 Consolidated PAT SBLC Amortisation bank by subsidiary intangible eliminated at assets acquired consolidation level 7
Slide 9: Management Commentary
Management Commentary Commenting on the performance, Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said: “Consolidated Revenue for FY26 stood at ₹ 423 crores, reflecting a growth of ~8% over FY25. PAT witnessed a decline in FY26 primarily due to increased depreciation and higher fin
Slide 10: Q4 & FY26 Standalone Profit & Loss Statement
Q4 & FY26 Standalone Profit & Loss Statement Particulars (in Rs. Crs) Q4FY26 Q4FY25 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 97.2 93.0 4.4% 332.9 314.2 6.0% Cost of Goods Sold 30.6 26.5 97.1 89.4 Gross Profit 66.6 66.6 0.0% 235.8 224.8 4.9% Gross Margin (%) 68.5% 71.6% -300 bps 70.8% 71.5% -70
Slide 11: Q4 & FY26 Consolidated Profit & Loss Statement
Q4 & FY26 Consolidated Profit & Loss Statement Particulars (in Rs. Crs) Q4FY26 Q4FY25 Y-o-Y FY26 FY25 Y-o-Y Revenue from Operations 120.9 112.7 7.3% 422.5 392.4 7.7% Cost of Goods Sold 41.2 37.9 138.9 129.4 Gross Profit 79.7 74.8 6.6% 283.6 263.0 7.9% Gross Margin (%) 65.9% 66.4% -40 bps 67.1% 67.0%
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Consolidated Assets (in Rs. Crs) Equity & Liabilities (in Rs. Crs) Mar-26 Mar-25 Mar-26 Mar-25 Non-Current Assets 920.1 837.5 Total Equity 634.7 630.2 Property Plant & Equipment 656.8 455.1 Share Capital 10.6 10.6 CWIP 158.6 232.9 Other Equity 624.0 619.6 Othe
Slide 13: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Consolidated Particulars (in Rs. Crs) FY26 FY25 Net Profit Before Tax 21.9 44.8 Adjustments for: Non -Cash Items / Other Investment or Financial Items 114.9 86.2 Operating profit before working capital changes 136.8 131.0 • Net cash from operating Changes in
Slide 14: About Tarsons
TRUST DELIVERED
Slide 15: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 16: Our Journey
Our Journey Established Product portfolio Commenced Pioneered the first fully manufacturing facility expansion & adding Established line for PCR production of Pipette robotic clean room expanding into depth in existing products in Jalan Tips, thereby creating a plant for manufacturing production of
Slide 17: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 18: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 19: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 20: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in- house ✓ Automated manufacturing with use of robotics & other technologies developed in collabor
Slide 21: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 16% of FY26 Domestic Sales East: 13% of FY26 Domestic Sales 43 Distributors 46 Distributors West: 29% of FY26 Domestic Sales 23 Distributors South
Slide 22: Huge underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2026, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 23: Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable Consumables Reusables Others 58.9% of FY26 38.1% of FY26 3.0% of FY26 Revenue Revenue Revenue • Portfolio o
Slide 24: Diversified product portfolio of Plastic Labware
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (59% of FY26 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 25: Foraying into cell culture segment
…foraying into cell culture segment Cell Culture Flask Cell Culture Plates Cell Culture Dishes Roller Bottles Support efficient and scalable cell culture Used to grow and maintain cells in a Used to grow and maintain cells in a applications. The smooth wall design controlled environment for research
Slide 26: Participation at Domestic Exhibition
Participation at Domestic Exhibition Analytica India 2026
Slide 27: Participation at International Exhibitions
Participation at International Exhibitions Analytica Germany 2026 WHX Dubai 2026
Slide 28: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 29: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Mr. Ramanathan Subramanian Suresh Prabhala Sanjive Sehgal Non-Executive Director Arun Kumar Chairman & Managing Director Non-Executive Nominee Director • Co-founder & Managing Partner at ADV Partners. • Partner & COO at ADV Partners with 25 • Investmen
Slide 30: Contribution towards Environmental, Social & Governance
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of NO litigations faced for pollution or contamination Use of Medical Grade degradation of environment over the Plastics. Products are designed to past five years Productivity optimisation with use o
Slide 31: Key Takeaways
Key Takeaways Leading Indian manufacturer of labware with an established brand Financial profile with Historical & focus on high-quality products strong EBITDA margin Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilities churning mu
Slide 32: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff / Mr. Tanay Shah santosh@tarsons.in sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98